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Abstract 
Background: The transcription factor 7‑like 2 (TCF7L2) is one of the genes that have been identified as possible 
determinants of diabetes which is associated with obesity. Data on the genetic causes of obesity in sub‑Saharan 
African populations are very scares. The aim of this study was to assess the association between the transcription 
factor 7‑like 2 (TCF7L2) gene polymorphism (rs12255372 G/T) and obesity and weight‑related traits in a Cameroonian 
population.
Methods: A case–control study was conducted on 35 obese and 30 non‑obese Cameroonian adults. TCF7L2 
rs12255372 genotypes were determined using PCR–RFLP and correlated with BMI and weight‑related traits.
Results: No significant association was observed between the rs12255372 T allele (χ2 = 0.0684, p = 0.79) or the 
TT genotype (χ2 = 0.372, p = 0.54) of the TCF7L2 gene and obesity in the Cameroonian population. However, 
amongst the weight‑related traits, triglycerides were significantly associated with the T risk allele of the TCF7L2 gene 
(p = 0.012).
Conclusion: This study on Cameroonian subjects replicates the absence of association between the TCF7L2 
rs12255372 variant and obesity as observed in European and American populations.
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Background
The rising prevalence of overweight and obesity consti-
tutes a global pandemic. The number of overweight and 
obese individuals increased from 857 million in 1980, to 
2.1 billion in 2013 [1]. In 2010, overweight and obesity 
were estimated to cause 3.4 million deaths, 4 % of years of 
life lost, and 4 % of disability-adjusted life-years (DALYs) 
worldwide [2]. In Cameroon, the prevalence of over-
weight or obesity among adults aged ≥15 years increased 
from 22.5 % in 2002 to 26 % in 2006 [3, 4].
Obesity results from an imbalance between energy 
intake and expenditure which is influenced by a variety 
of multiple factors that could be environmental, psycho-
social and genetic [5]. Although this epidemic is attrib-
utable to the trend of decreased physical activity and 
increased calorie intake, these external factors play out 
on a genetic background that determines body mass 
and susceptibility to obesity-related diseases [6] and so, 
common forms of obesity have a strong hereditary com-
ponent. Depending on the population examined, these 
genetic factors may account for 6–85 % of the cases [7]. 
However, the genetic pathways that contribute to obesity 
have not yet been elucidated.
The transcription factor 7-like 2 (TCF7L2) gene 
is one of those that have been identified as possible 
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determinants of type 2 diabetes mellitus (T2DM). It 
codes for a transcription factor with a high-mobility 
box which is one of the components of the Wingless 
type (Wnt) signaling pathway, initially characterized in 
colon cancer and in the embryonic development of some 
organisms such as Drosophila [8]. Wnt pathways are a 
group of signal transduction pathways made of proteins 
that pass signals from outside of a cell through cell sur-
face receptors to the inside of the cell. Three have been 
characterized including the canonical Wnt pathway, the 
non-canonical planar cell polarity pathway and the non-
canonical Wnt/calcium pathway. It has been shown that 
in adipocytes, the canonical Wnt-signaling via TCF7L2 
down-regulates adipogenesis [9]. Although TCF7L2 
was not identified as a risk factor for obesity in a study 
involving European populations, its effect on the risk 
for T2DM was modulated by obesity [10]. Additionally, 
a study revealed that the rs12255372 variant of TCF7L2 
was protective for obesity in Mexican children [11]. 
These findings warrant further investigation of the role 
of TCF7L2 in obesity among various ethnic populations. 
We previously reported on the rs12255372 (G/T) and 
rs7903146 (C/T) polymorphisms of TCF7L2 as risk fac-
tors for type 2 diabetes mellitus in a Cameroonian pop-
ulation [12, 13], however to the best of our knowledge, 
the association between rs12255372 (G/T) and obesity 
has not been explored in any African population till date. 
The aim of this study therefore was to assess the possi-
ble association of the TCF7L2 rs12255372 polymorphism 
with obesity and weight-related traits in a Cameroonian 
population. Findings may contribute to further investiga-
tions for the understanding of the causal role of heredity 




A case–control study was conducted that involved 
35 obese (BMI  ≥  30  kg/m2) and 30 non-obese 
(18  ≤  BMI  <  25  kg/m2) adults of Cameroonian origin, 
aged 20 years and above. Obese patients were recruited 
from the Outpatients Clinic of the National Obesity 
Center of the Yaoundé Central Hospital, and non-obese 
controls from the general population between February 
and April 2011. Diabetic patients and pregnant women 
were excluded from the study. For all participants, data 
was collected on the sex and age. Height, waist and hip 
circumference to the nearest 0.5  cm were measured, 
as well as weight in light clothes to the nearest 0.1  kg. 
The body mass index (BMI) as weight in kg divided by 
height in meters squared (m2), and the waist-to-hip 
ratio as waist circumference (cm) divided by hip circum-
ference (cm) were calculated. Obesity was defined as 
BMI ≥ 30 kg/m2. The resting blood pressures were meas-
ured using standardized procedures with an automatic 
sphygmomanometer Omron HEM-705 CP (Omron Cor-
poration, Tokyo, Japan).
Biochemical assays
Fasting plasma glucose (glucose oxidase–peroxidase 
method), serum cholesterol (cholesterol oxidase phe-
nol-4-amino antipyrene peroxidase method), serum 
triglycerides (glycerol phosphatase oxidase phenol-
4-amino antipyrene peroxidase method), and high-den-
sity lipoprotein (HDL)-cholesterol (cholesterol oxidase 
phenol-4-amino antipyrene peroxidase method) were 
measured on a spectrophotometer (UV Mini 1240) using 
Chronolab kits (Chronolab Systems, Barcelona, Spain). 
Low-density lipoprotein (LDL)-cholesterol was calcu-
lated using the Friedwald’s formula [14].
DNA extraction and molecular genotyping
DNA was extracted from whole blood on filter paper 
by the Chelex method. Sixty-five participants (35 obese 
patients and 30 controls) were genotyped for TCF7L2 
rs12255372 by polymerase chain reaction–restric-
tion fragment length polymorphism (PCR–RFLP). The 
TCF7L2 rs12255372 (G/T) polymorphism was geno-
typed using the following primers: forward 5′-CTG GAA 
ACT AAG GCG TGA GG-3′, reverse 5′-GGG TCG 
ATG TTG TTG AGC TT-3′ (SIGMA-ALDRICH, St. 
Louis, Missouri, USA). A final reaction volume of 15 μL 
for the PCR was constituted which contained 100 ng of 
genomic DNA, 5 pmol of each primer, PCR buffer with 
1 mmol/L of MgCl2, 100 μmol/L of each deoxynucleotide 
triphosphate (dNTP), 0.5 U of Hot Star Taq DNA poly-
merase (QIAGEN) and 7.8 µl of nuclease-free water. The 
PCR was carried out in a BIOMETRA T3 Thermal Cycler 
under the following conditions: 95  °C for 15  min, fol-
lowed by 34 cycles of 95 °C for 30 s, 54 °C for 30 s, 72 °C 
for 30 s, and a final extension of 72 °C for 9 min. The PCR 
amplicons (346 bp) were then digested with Thermus spe-
cies (Tsp 5091) restriction enzyme at 37  °C overnight. 
The reaction volume was set to 15  μl, containing 7  μl 
of amplicons, 1× NEB buffer1. The resulting products 
were separated by electrophoresis on a 3  % agarose gel 
using a 100  bp DNA ladder and visualized under a UV 
transilluminator.
Statistical analyses
Allele and genotype frequencies in patients and con-
trol subjects were estimated by direct counting. Quali-
tative variables were analyzed by the Chi Square (χ2) 
test with Yates’ Continuity correction or the Exact test 
when appropriate using Epi Info version 6 (USD, Stone 
Mountain, USA). Quantitative variables were analysed 
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by Mann–Whitney U test statistics using IBM SPSS for 
Windows version 20.0 (SPSS, Inc., Chicago, IL, USA). 
P  <  0.05 was considered statistically significant and in 
case of multiple comparisons, the conservative Bonfer-
roni correction was applied. The relative risks (RR) were 
calculated as odd ratios (OR) with 95 % confidence inter-
val (CI) using Woolf ’s formula.
Ethical considerations
The study was granted approval by the National Ethi-
cal Review Board of the Cameroon Ministry of Public 
Health. Written informed consent was obtained from all 
the participants. The study was conducted in accordance 
with the Helsinki Declaration.
Results
Characteristics of the study population
Table  1 shows anthropometric features, blood pressure 
and metabolic profile of the study population. Significant 
differences between obese patients and health controls 
were observed for age (median age—46.00 vs 25.00 years, 
p  <  0.0001), waist-to-hip ratio (median value—0.8600 
vs 0.8100, p < 0.0001), diastolic blood pressure (median 
value—80.00 vs 68.00  mmHg, p  <  0.0040) and BMI 
(median value—32.76 vs 22.39  kg/m2, p  <  0.0001). All 
participants were positively genotyped. The respec-
tive fragments for the different genotypes were as fol-
lows. The wild type homozygote GG genotype had two 
band appearing at 143 and 104 bp; the mutant homozy-
gote TT had two bands appearing at 126 and 104 bp and 
the mutant heterozygote GT had three bands appearing 
at 143, 126 and 104  bp. Fragments smaller than 100  bp 
migrated out of the gel and were not visualized (Figs. 1, 
2).
Genetic association assessment
The TCF7L2 rs12255372 (G/T) SNP was in Hardy–Wein-
berg equilibrium in the general population (χ2 = 0.0500, 
p = 0.8300). The association between TCF7L2 and obe-
sity in Cameroon was determined by comparing the 
allele and genotype frequencies of rs12255372 (G/T) in 
the 35 obese patients and 30 healthy controls (Table 2). 
The allelic frequencies obtained in the general population 
were 18.35 % for the T allele and 81.65 % for the G allele. 
In the case–control analysis, no significant difference was 
observed in the allelic and genotypic frequencies between 
the obese and non-obese groups (χ2 = 0.0684, p = 0.7900 
for allele and χ2 = 0.3720, p = 0.5400 for genotype).
Genotype–phenotype correlation
Genotype–phenotype correlations were performed to 
investigate the association of TCF7L2 rs12255372 and 
metabolic parameters in lean and obese individuals. 
These case–control analyses were performed accord-
ing to demographic (sex and age at onset), clinical (body 
mass index, waist-to-hip ratio, systolic and diastolic 
blood pressure) and biological (fasting plasma glucose, 
total cholesterol, HDL, LDL and triacylglycerol) charac-
teristics. T allele carriers in the obese group had a signifi-
cantly higher triglyceride levels when compared to their 
non-obese counterparts (p < 0.0120).
Discussion
TCF7L2 has been associated with fasting plasma insulin, 
with glucose levels in type 2 diabetes patients to some 
Table 1 Characteristics of the study population
Data are medians (interquartile range) unless otherwise stated
WHR waist-to-hip ratio, SBP systolic blood pressure, DBP diastolic blood pressure, 
BMI body mass index, FPG fasting plasma glucose, TC total cholesterol, HDL 
high density lipoprotein cholesterol, LDL low density lipoprotein cholesterol, TG 
triglycerides
Characteristics Non-obese (n = 30) Obese (n = 35) P value
Demographic
 Sex, % of male 33.3 % 8.6 % 0.028
 Age (years) 25.00 (23.00–36.50) 46.00 (39.00–53.00) <0.0001
Clinical
 WHR ratio 0.81 (0.77–0.84) 0.86 (0.83–0.93) <0.0001





 DBP (mmHg) 68.00 (61.75–85.00) 80.00 (75.00–88.00) 0.004
 BMI (kg/m2) 22.39 (21.11–23.93) 32.76 (30.94–35.72) <0.0001
Biological
 FPG (g/L) 90.00 (83.00–103.25) 96.00 (86.00–103.00) 0.392







46.79 (42.71–50.16) 47.96 (43.70–51.72) 0.247
 LDL‑C (mg/dL) 100.05 (92.87–120.24) 106.97 (94.08–135.88) 0.490





Fig. 1 Electrophoregram of amplified rs 12255372 portion of the 
TCF7L2 gene. C negative control, MwM molecular weight marker 
(100 bp ladder), 1–9 tested samples, bp base pair
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extent with BMI [10, 15, 16], and with adipogenesis [9]. 
It is one of the genes that have been identified as possi-
ble determinants of diabetes. Data on genetic suscepti-
bility of African populations to chronic disease are very 
scarce [17]. The aim of this study was to assess the possi-
ble association of the TCF7L2 rs12255372 polymorphism 
with obesity and weight-related traits in a Cameroonian 
population. This case–control association analysis dem-
onstrates the absence of association between the poly-
morphism and obesity. This finding is similar to those of 
Cauchi et al. [10] and Saxena et al. [18] who also found 
no genetic association between TCF7L2 and obesity in 
European and US populations, respectively, especially 
for the rs7903146 and rs10885406 polymorphisms. How-
ever, some other studies reported a tendency for nega-
tive association with BMI [10, 19]. Nevertheless, these 
results are different from those of Klunder et  al. that 
showed a protective association between rs12255372 
polymorphism and obesity in Mexican children, while a 
deleterious effect of this variant was observed in diabetic 
adults [11]. Moreover, the background frequencies of the 
TCF7L2 rs12255372 alleles and genotypes were differ-
ent between the Cameroonian and Mexican populations 
indicating genetic heterogeneity across populations and 
ancestries on this locus. The frequency of this risk allele 
has been observed to be highest in a study in Caucasians 
Fig. 2 Electrophoregram of digested amplicons with Tsp 5091. C negative control, MwM molecular weight marker (100 bp ladder), 1–6 and 1–7 
tested samples, bp base pair
Table 2 Case–control association analysis of TCF7L2 rs12255372 (G/T) with obesity
RR (relative risks) were calculated as odd ratios (OR) with 95 % CI using Woolf’s formula. When one of the entries was zero, OR was calculated using Woolf’s formula 
with Haldane’s modification
a Data are given as n (%) unless otherwise stated
TCF7L2 rs12255372 G/T Non-obesea Obesea Test statistics P value OR (95 % CI)
Alleles
 G 50 (83.3) 56 (80) χ2 = 0.0684 0.79 0.51 (1.25–3.06)
 T 10 (16.7) 14 (20) χ2 = 0.0684 0.79 0.33 (0.80–1.96)
 Total (2n) 60 70
Genotypes
 G/G 21 (70) 22 (62.9) χ2 = 0.118 0.73 1.38 (0.49–3.90)
 G/T 8 (26.7) 12 (34.3) χ2 = 0.155 0.69 0.70 (0.23–2.03)
 T/T 1 (3.3) 1 (2.9) χ2 = 0.372 0.54 1.17 (0.07–19.59)
 Total (n) 30 35
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(77 %) with 42 % in cases (diabetics) and 35 % in controls 
[20] and lowest in Asians (1 %) with 0.6 % in cases and 
0.4 % in controls [21].
Studies have shown that some variants of TCF7L2 are 
associated with impaired lipid metabolism, especially a 
trend towards higher triglycerides, with an adverse effect 
on cardiovascular risk and stroke incidence [22, 23]. 
Meta-analyses have been conducted to confirm the asso-
ciation from individual studies. These studies (meta-anal-
yses) further support the association between TCF7L2 
gene and metabolic diseases including diabetes and obe-
sity. Among the common studied allele, rs12255372 vari-
ant of the TCF7L2 gene is significantly associated with 
susceptibility to T2DM in the global population [24] 
while the other allele (rs7903146) is associated with met-
abolic syndrome [25] of which dyslipidemia is a predictor. 
TCF7L2 rs12255372 has also been found to be associ-
ated with high serum triglycerides and was differentially 
expressed in adipose tissue in families with familial com-
bined hyperlipidaemia [26]. Genotype–phenotype cor-
relation assessment in our study revealed that the gene 
was preferentially associated with high triglyceride levels. 
Carriers of the T risk allele had a significantly higher tri-
glyceride level when compared to carriers of the G allele 
(p < 0.0120). This finding suggests a possible association 
between the TCF7L2 rs12255372 variant and cardiovas-
cular risk in the Cameroonian population. Further stud-
ies are therefore required to confirm these findings and 
then investigate the nature of the association.
Conclusion
TCF7L2 rs12255372 was not associated with obesity in 
this Cameroonian population, but was associated with 
higher triglyceride levels in obese patients. Due to the 
small sample size of the study and the lack of power to 
detect an association, other studies carried with a larger 
sample size and matched for age and sex are required to 
confirm these findings.
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